Abuse-resistant transdermal dosage form
Assignee3M Innovative Properties Company
InventorsJohn R. Hart, Deanna L. Stebbings
Life of this patent
Estimating the term…
Abstract
The invention comprises a transdermal dosage form comprising a active agent component comprising a polymeric matrix and an abusable drug substance, an overlay backing, a porous material, and an antagonist reservoir comprising an antagonist to the abusable drug substance. The porous material adjoins the antagonist reservoir and is in fluid communication with the skin-contacting surface defined by the active agent component. In one embodiment, the device comprises a barrier layer interposed between the active agent component and the antagonist reservoir.
Claims30
A transdermal dosage form comprising:
- an active agent component comprising a polymeric material and an active agent, wherein the active agent component has a proximal, skin-contacting surface and a distal surface opposed to the proximal surface;
- an overlay backing;
- an adverse agent component comprising an antagonist to the abusable drug substance, wherein the adverse agent component is interposed between the distal surface of the active agent component and the overlay backing;
- and
- a porous material adjacent to and adjoining the adverse agent component;
- wherein the porous material is in fluid communication with the proximal surface of the active agent component.
A transdermal dosage form comprising:
- a release liner;
- an overlay backing;
- an active agent component interposed between the release liner and the overlay backing, wherein the active agent is in diffusional communication with the release liner;
- a barrier interposed between the active agent component and the overlay backing;
- an adverse agent component comprising an antagonist to the active agent, wherein the adverse agent component is interposed between the barrier and the overlay backing;
- and
- a porous material adjacent to and adjoining the adverse agent component;
- wherein the porous material is in fluid communication with the release liner.
Dependencies are inferred from the claim text.